Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study.
Journal of Clinical Oncology.
Times cited: 482
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study.
The Lancet Oncology.
Times cited: 390